...
首页> 外文期刊>Human Pathology >Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy.
【24h】

Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy.

机译:多药耐药相关蛋白1与鼻咽癌放疗和同步化疗患者预后不良之间的关系。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

ATP-binding cassette (ABC) multidrug transporters have been associated with chemoresistance, which is a major obstacle in attempts to improve clinical outcome of patients with nasopharyngeal carcinoma (NPC). In this study, we investigated 3 ABC multidrug transporters including MDR1, MRP1, and BCRP for their potential as prognostic indicators in patients with NPC. We examined the protein expression profiles of MDR1, MRP1, and BCRP in NPC tissues from 60 patients with advanced stages who were treated with radiotherapy and concurrent chemotherapy. The clinicopathologic features, patterns of treatment failure, and survival data were compared with the transporter expression. Univariate analyses were performed to determine the prognostic factors that influenced treatment failure and patient survival. We found that MRP1 expression was strongly predictive of both 5-year survival (P = .025) and disease-free survival (P .001). However, neither MDR1 nor BCRP expression was correlated with the clinicopathologic parameters. Interestingly, the incidence of recurrence and metastasis for patients in the MRP1-positive group was significantly higher than that in the MRP1-negative group (P = .003). With multivariate analysis, MRP1 expression at the time of diagnosis before the treatment was identified as an independent prognostic factor for both 5-year survival (P = .041) and disease-free survival (P = .001). MRP1 expression can therefore be used as a potent molecular risk factor and a guide for chemotherapeutic regimens in patients with advanced stages of NPC.
机译:ATP结合盒(ABC)多药转运蛋白已与化学抗性相关联,这是试图改善鼻咽癌(NPC)患者临床结局的主要障碍。在这项研究中,我们调查了3种ABC多药转运蛋白(包括MDR1,MRP1和BCRP)作为NPC患者预后指标的潜力。我们检查了60例接受放疗和同步化疗的晚期患者的NPC组织中MDR1,MRP1和BCRP的蛋白表达谱。将临床病理特征,治疗失败模式和生存数据与转运蛋白表达进行比较。进行单因素分析以确定影响治疗失败和患者生存的预后因素。我们发现,MRP1表达可强烈预测5年生存期(P = .025)和无病生存期(P <.001)。但是,MDR1和BCRP表达均与临床病理参数无关。有趣的是,MRP1阳性组患者的复发和转移发生率显着高于MRP1阴性组(P = .003)。通过多变量分析,确定治疗前诊断时的MRP1表达是5年生存率(P = .041)和无病生存率(P = .001)的独立预后因素。因此,MRP1表达可以作为有效的分子危险因素和晚期NPC患者的化疗方案指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号